Department of Medical Physiology and Biophysics, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Department of Dermatology, Hospital Universitario Virgen del Rocío, Seville, Spain.
Am J Clin Pathol. 2019 Sep 9;152(4):446-457. doi: 10.1093/ajcp/aqz066.
OBJECTIVES: Study of aquaporin 1 (AQP1) and aquaporin 3 (AQP3) expression to understand its potential role in the pathophysiology of skin cancer. METHODS: Analysis of AQP1 and AQP3 expression by immunohistochemistry of 72 skin biopsy specimens from melanocytic skin tumors, nonmelanocytic tumors, or healthy samples. RESULTS: AQP1 showed strong labeling in 100% of benign common melanocytic nevi. Small blood vessels, stroma, and melanophages surrounding different types of melanomas tumors also were positive. Tumoral melanocytes in atypical nevi and melanomas were negative for AQP1. AQP3 showed strong labeling in 100% of melanocytic nevi, 100% of atypical melanocytic nevi, and 100% of melanomas. In all basal cell carcinomas and squamous cell carcinomas, staining for AQP3 was positive. CONCLUSIONS: To our knowledge, this work represents the first demonstration of AQP1/AQP3 expression in human melanocytic skin tumors. More studies are needed to understand the underlying molecular mechanisms of expression of both AQPs in melanocytic tumors and their potential as molecular therapeutic targets.
目的:研究水通道蛋白 1(AQP1)和水通道蛋白 3(AQP3)的表达,以了解其在皮肤癌病理生理学中的潜在作用。
方法:通过免疫组织化学分析 72 例皮肤活检标本中 AQP1 和 AQP3 的表达,这些标本来自黑素细胞性皮肤肿瘤、非黑素细胞性肿瘤或健康样本。
结果:100%的良性常见黑素细胞痣中 AQP1 呈强标记。不同类型黑素瘤肿瘤周围的小血管、基质和黑素细胞也呈阳性。非典型痣和黑素瘤中的肿瘤性黑素细胞对 AQP1 呈阴性。AQP3 在 100%的黑素细胞痣、100%的非典型黑素细胞痣和 100%的黑素瘤中呈强标记。所有基底细胞癌和鳞状细胞癌中,AQP3 的染色均为阳性。
结论:据我们所知,这项工作首次证明了 AQP1/AQP3 在人类黑素细胞性皮肤肿瘤中的表达。需要更多的研究来了解这两种 AQP 在黑素细胞性肿瘤中的表达的潜在分子机制及其作为分子治疗靶点的潜力。
Am J Clin Pathol. 2019-9-9
Virchows Arch A Pathol Anat Histopathol. 1993
Hum Pathol. 2009-12-11
Am J Dermatopathol. 2021-11-1
Am J Dermatopathol. 1998-6
J Cutan Pathol. 2009-4
Ann Diagn Pathol. 2005-8
Cell Commun Signal. 2024-2-9
Adv Exp Med Biol. 2023
Biomedicines. 2021-1-21
Int J Mol Sci. 2020-4-2